Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
12.58
+0.15 (1.21%)
At close: Dec 5, 2025, 4:00 PM EST
14.00
+1.42 (11.29%)
After-hours: Dec 5, 2025, 7:59 PM EST
Ocular Therapeutix Employees
Ocular Therapeutix had 274 employees as of December 31, 2024. The number of employees increased by 7 or 2.62% compared to the previous year.
Employees
274
Change (1Y)
7
Growth (1Y)
2.62%
Revenue / Employee
$203,588
Profits / Employee
-$911,215
Market Cap
2.68B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OCUL News
- 1 day ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R - GlobeNewsWire
- 2 months ago - Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewsWire
- 2 months ago - Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript - Seeking Alpha
- 2 months ago - Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock - GlobeNewsWire
- 2 months ago - Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint - GlobeNewsWire